David Nierengarten
Stock Analyst at Wedbush
(3.18)
# 1,011
Out of 4,873 analysts
217
Total ratings
40%
Success rate
2.39%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Reiterates: Outperform | $715 | $558.52 | +28.02% | 21 | Jun 24, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $3.77 | +191.78% | 4 | Jun 23, 2025 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $15.90 | +38.36% | 2 | Jun 12, 2025 | |
| NUVB Nuvation Bio | Maintains: Outperform | $5 | $2.00 | +150.00% | 9 | Jun 11, 2025 | |
| BPMC Blueprint Medicines | Downgrades: Neutral | $128 → $129 | $128.24 | +0.59% | 5 | Jun 2, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Neutral | $10 → $12 | $10.09 | +18.93% | 3 | May 28, 2025 | |
| NTLA Intellia Therapeutics | Reiterates: Neutral | $10 | $9.53 | +4.99% | 9 | May 19, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $29 → $27 | $17.00 | +58.82% | 8 | Apr 16, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Reiterates: Outperform | $34 | $29.06 | +17.00% | 3 | Apr 16, 2025 | |
| IMNM Immunome | Reiterates: Outperform | $33 | $8.92 | +269.96% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $0.85 | +136.69% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.18 | +323.73% | 15 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $9.58 | +223.59% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $46.95 | +64.00% | 6 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $23.32 | +71.53% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $44.00 | +104.55% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $34.08 | +37.91% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $3.99 | +275.94% | 6 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $99 → $115 | $77.00 | +49.36% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $5.16 | +345.74% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $10.33 | +93.61% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $11.76 | +240.14% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $15.79 | +184.99% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.64 | +509.76% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $1.62 | +1,011.11% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $54.32 | +4.93% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.36 | +1,277.41% | 8 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.36 | +47.06% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $7.24 | +38.12% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $0.31 | +3,420.00% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $36 | $8.51 | +323.03% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $2.41 | +397.93% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $17.09 | +233.53% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $7 | $0.34 | +1,971.01% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $2.93 | +16,964.85% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $4.62 | +1,198.70% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $8.45 | +124.85% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $37.16 | +101.83% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.08 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.00 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.97 | - | 3 | Nov 20, 2017 |
argenx SE
Jun 24, 2025
Reiterates: Outperform
Price Target: $715
Current: $558.52
Upside: +28.02%
Perspective Therapeutics
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $3.77
Upside: +191.78%
Telix Pharmaceuticals
Jun 12, 2025
Reiterates: Outperform
Price Target: $22
Current: $15.90
Upside: +38.36%
Nuvation Bio
Jun 11, 2025
Maintains: Outperform
Price Target: $5
Current: $2.00
Upside: +150.00%
Blueprint Medicines
Jun 2, 2025
Downgrades: Neutral
Price Target: $128 → $129
Current: $128.24
Upside: +0.59%
iTeos Therapeutics
May 28, 2025
Downgrades: Neutral
Price Target: $10 → $12
Current: $10.09
Upside: +18.93%
Intellia Therapeutics
May 19, 2025
Reiterates: Neutral
Price Target: $10
Current: $9.53
Upside: +4.99%
NovoCure
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $17.00
Upside: +58.82%
Kiniksa Pharmaceuticals International,
Apr 16, 2025
Reiterates: Outperform
Price Target: $34
Current: $29.06
Upside: +17.00%
Immunome
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $8.92
Upside: +269.96%
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.85
Upside: +136.69%
Mar 6, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.18
Upside: +323.73%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $9.58
Upside: +223.59%
Feb 12, 2025
Reiterates: Outperform
Price Target: $77
Current: $46.95
Upside: +64.00%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $23.32
Upside: +71.53%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $44.00
Upside: +104.55%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $34.08
Upside: +37.91%
Sep 30, 2024
Reiterates: Outperform
Price Target: $15
Current: $3.99
Upside: +275.94%
Sep 16, 2024
Maintains: Outperform
Price Target: $99 → $115
Current: $77.00
Upside: +49.36%
Sep 10, 2024
Reiterates: Outperform
Price Target: $23
Current: $5.16
Upside: +345.74%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $10.33
Upside: +93.61%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $11.76
Upside: +240.14%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $15.79
Upside: +184.99%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.64
Upside: +509.76%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $1.62
Upside: +1,011.11%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $54.32
Upside: +4.93%
Aug 8, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.36
Upside: +1,277.41%
May 29, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.36
Upside: +47.06%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $7.24
Upside: +38.12%
May 10, 2024
Reiterates: Outperform
Price Target: $11
Current: $0.31
Upside: +3,420.00%
May 10, 2024
Maintains: Outperform
Price Target: $34 → $36
Current: $8.51
Upside: +323.03%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $2.41
Upside: +397.93%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $17.09
Upside: +233.53%
Feb 29, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $0.34
Upside: +1,971.01%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $2.93
Upside: +16,964.85%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $4.62
Upside: +1,198.70%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $8.45
Upside: +124.85%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $37.16
Upside: +101.83%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.08
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.00
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $5.97
Upside: -